<a href="https://www.fiercebiotech.com/biotech/astrazeneca-scraps-flap-inhibitor-flunked-phase-2-asthma-trial" hreflang="en">AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial</a>
AstraZeneca has discontinued its FLAP inhibitor, atuliflapon, after it failed to show efficacy in a phase 2 asthma trial involving 666 patients. The company also ended work on three other programs as part of a strategic portfolio prioritization.
AstraZeneca's decision to scrap its FLAP inhibitor for asthma after phase 2 trial failure highlights the challenges in developing targeted therapies within the leukotriene pathway, as no FLAP inhibitors have reached the market despite significant investment. This suggests a potential reevaluation of strategic priorities for companies investing in similar pathways or asthma treatments, and underscores the importance of robust early-stage clinical data in high-risk areas like inflammation and immunity.